Sangamo BioSciences | SGMO - Ebit


Sangamo BioSciences reported $-72.22M in EBIT for its fiscal quarter ending in June of 2023.





Ebit Change Date
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 4.61B 777M Jun/2026
Bayer EUR 755M 2.77B Jun/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 116M Dec/2025
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Grifols EUR 320.55M 91.01M Dec/2025
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.73B 549M Jun/2026
Omeros USD -48.15M 7.25M Sep/2023
Pfizer USD -180M 5.16B Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 1.12B 811M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026